Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $1.84, $0.37 better than the analyst estimate of $1.47. Revenue for the quarter came in at $707.1 million versus the consensus estimate of $691.09 million.

GUIDANCE:

Charles River Laboratories sees FY2020 EPS of $6.75-$7.10, versus the consensus of $6.44.

The Company’s revised guidance for revenue growth, earnings per share, and free cash flow is as follows:

2020 GUIDANCE		CURRENT		PRIOR
Revenue growth, reported		4.5% – 8.0%		13.0% – 14.5%
Less: Contribution from acquisitions (1)		~(4.0%)		(4.0%) – (4.5%)
Unfavorable/(favorable) impact of foreign exchange		0.5% – 1.0%		(1.0%) – (1.5%)
Revenue growth, organic (2)		1.5% – 4.5%		7.75% – 8.75%
GAAP EPS estimate		$4.25 – $4.60		$5.20 – $5.35
Acquisition-related amortization (3)		$1.75 – $1.80		$1.65 – $1.70
Charges related to global efficiency initiatives (4)		~$0.05		<$0.05
Acquisition-related adjustments (5)		~$0.20		~$0.25
Other items (6)		$0.25 – $0.32		$0.25 – $0.32
Venture capital investment losses/(gains) (7)		$0.18		--
Non-GAAP EPS estimate		$6.75 – $7.10		$7.45 – $7.60
Free cash flow (8)		$325 – $350 million		$350 – $360 million

Footnotes to Guidance Table:

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.